ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2556

A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE

Joyce Chang1, Jessica Liu1, Emily Smitherman2, Pooja Patel3, Gabrielle Alonzi1, Gabrielle Morgan4, Livie Timmerman5, Laura Berbert6, Edie Weller1, Karen Costenbader7 and Mary Beth Son8, 1Boston Children's Hospital, Boston, MA, 2University of Alabama at Birmingham, Birmingham, AL, 3Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 5University of Alabama at Birmingham, Gardendale, AL, 6Boston Children's Hospital, Belmont, MA, 7Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 8Boston Children's Hospital, Brookline, MA

Meeting: ACR Convergence 2024

Keywords: Access to care, Disparities, Epidemiology, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Healthcare Disparities in Rheumatology

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Child opportunity is defined as the neighborhood resources and conditions that promote healthy childhood development. We determined whether low neighborhood-level opportunity associates with more severe disease presentation or higher acute care utilization after diagnosis in a geographically and socioeconomically diverse, multi-center cohort of patients with childhood-onset systemic lupus erythematosus (cSLE).

Methods: We identified patients with cSLE at 3 tertiary centers (Boston Children’s Hospital (BCH), Lurie Children’s Hospital of Chicago (LCH), and Children’s Hospital of Alabama (COA), 2016-2022) with valid U.S. street addresses and linked their medical records to census tract-level data. The index visit was the first visit with a physician diagnosis of SLE. The primary outcomes were severe initial disease presentation (composite of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) ≥10, intensive care admission, or dialysis) and acute care utilization (inpateient or emergency visits) within the first year after the index visit. The secondary outcome was concurrent achievement of SLEDAI-2K < =4 and prednisone-equivalent dose < =7.5 mg/day at the most recent follow-up visit. The exposure of interest was census tract-level Child Opportunity Index (COI) 2.0 (29 indicators across education, socioeconomic status, physical environment), ranked nationally. Associations between COI and outcomes were estimated using logistic or negative binomial regression accounting for clustering by site. Patient-level covariates included age at SLE onset, sex, race and ethnicity reported in the medical record, English vs. non-English primary language and insurance status.

Results: We included 148 patients with cSLE at BCH, 265 at LCH, and 138 at COA. Of 538 patients with evaluable COI linkages, 50% were publicly insured, 29% reported Black race, 30% reported Hispanic ethnicity, and 14% had a preferred language other than English (Table 1). COA had the highest proportion of Black patients (59%) while LCH had the highest proportion of Hispanic patients (43%). COI was on average higher at BCH compared to LCH and COA (Fig. 1). 50% of cSLE patients met criteria for severe presentation, and the median number of inpatient/emergency visits in the 1st year was 1 [range 1-13]. Living in areas with low vs. very high COI associated with 1.93 higher adjusted odds of severe presentation (95% CI [1.05-3.57]; Fig. 2A), 2.03 higher adjusted incidence of acute care utilization during the first year of follow-up (95% CI [1.29-3.18]; Fig. 2B and Table 1), and 0.47 lower odds of achieving SLEDAI-2K < =4 and prednisone < =7.5 mg/day adjusted for severe disease presentation (95% CI [0.23–0.94]; Fig. 2C).

Conclusion: Higher cSLE disease severity at presentation to care and lower likelihood of achieving disease targets after establishing subspecialty care were associated with living in areas with lower child opportunity, which may represent structural barriers to care and effects of toxic stress, among other socio-environmental factors. Tailoring community-based interventions to neighborhoods with low levels of child opportunity may reduce disparities at multiple points of access to pediatric subspecialty care.

Supporting image 1

Supporting image 2

Figure 1. Percentage of children with SLE living in census tracts at each level of nationally-ranked Child Opportunity Index (COI), by site of care.

Supporting image 3

Figure 2. A) Estimated odds of having a severe disease presentation (composite of SLEDAI_2K >=10, ICU admission or dialysis) at the first visit to each center, B) incidence rates of inpatient and emergency care visits within the first year of follow-up, and C) odds of achieving low disease activity (defined by SLEDAI_2K <=4 and prednisone-equivalent dose <= 7.5 mg/day) at the most recent visit, for children living in census tracts in each level of child opportunity index (COI) compared to those living in very high opportunity areas according to nationally ranked COI levels across all 3 sites. All estimates are adjusted for age at index visit, sex assigned at birth, race and ethnicity as reported in the electronic medical record, English vs. non-English preferred primary language, and insurance type, and include a random effect for site of care. Estimates in B) are additionally adjusted for initial SLEDAI_2K scores at initial presentation (index visit), and estimates in C) are additionally adjusted for severe disease presentation and duration between the index visit and most recent visit date. Asterisks represent statistically significant results (p-value <0.05, 2-tailed).


Disclosures: J. Chang: Century Therapeutics, 2; J. Liu: None; E. Smitherman: None; P. Patel: CVS, 3, 11; G. Alonzi: None; G. Morgan: None; L. Timmerman: None; L. Berbert: None; E. Weller: None; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bain HealthSciences, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta Bio, 2, 5, Exagen, 5, Gilead, 5, Glaxo Smith Kline, 2, 5, Merck, 5; M. Son: None.

To cite this abstract in AMA style:

Chang J, Liu J, Smitherman E, Patel P, Alonzi G, Morgan G, Timmerman L, Berbert L, Weller E, Costenbader K, Son M. A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-multi-center-study-of-associations-between-neighborhood-level-child-opportunity-initial-disease-severity-and-acute-care-utilization-among-children-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multi-center-study-of-associations-between-neighborhood-level-child-opportunity-initial-disease-severity-and-acute-care-utilization-among-children-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology